Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
19.17 USD | -0.52% | -4.67% | +9.29% |
May. 14 | Transcript : Kiniksa Pharmaceuticals, Ltd. Presents at Bank of America Health Care Conference 2024, May-14-2024 10:40 AM | |
Apr. 23 | Kiniksa Pharmaceuticals Q1 Loss Widens, Revenue Rises | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- The company presents an interesting fundamental situation from a short-term investment perspective.
- According to Refinitiv, the company's ESG score for its industry is poor.
Strengths
- According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
- The earnings growth currently anticipated by analysts for the coming years is particularly strong.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- For several months, analysts have been revising their EPS estimates roughly upwards.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
- Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- The company appears highly valued given the size of its balance sheet.
- The valuation of the company is particularly high given the cash flows generated by its activity.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+9.29% | 1.37B | C- | ||
+10.79% | 115B | B+ | ||
+11.65% | 106B | B+ | ||
-6.20% | 24.69B | B+ | ||
-2.33% | 21.97B | B | ||
-6.03% | 19.27B | A- | ||
-13.41% | 17.56B | B | ||
-40.50% | 17.32B | A- | ||
+6.64% | 14.03B | C+ | ||
+31.84% | 12.13B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- KNSA Stock
- Ratings Kiniksa Pharmaceuticals, Ltd.